Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

iPSCs and small molecules: a reciprocal effort towards better approaches for drug discovery.

Zhang R, Zhang LH, Xie X.

Acta Pharmacol Sin. 2013 Jun;34(6):765-76. doi: 10.1038/aps.2013.21. Epub 2013 Apr 22. Review.

2.

New lessons learned from disease modeling with induced pluripotent stem cells.

Onder TT, Daley GQ.

Curr Opin Genet Dev. 2012 Oct;22(5):500-8. doi: 10.1016/j.gde.2012.05.005. Epub 2012 Jun 28. Review.

3.

Disease modeling and drug screening for neurological diseases using human induced pluripotent stem cells.

Xu XH, Zhong Z.

Acta Pharmacol Sin. 2013 Jun;34(6):755-64. doi: 10.1038/aps.2013.63. Epub 2013 May 20. Review.

4.

Induced pluripotent stem cells--opportunities for disease modelling and drug discovery.

Grskovic M, Javaherian A, Strulovici B, Daley GQ.

Nat Rev Drug Discov. 2011 Nov 11;10(12):915-29. doi: 10.1038/nrd3577. Review.

PMID:
22076509
5.

Induced pluripotent stem cells for regenerative cardiovascular therapies and biomedical discovery.

Nsair A, MacLellan WR.

Adv Drug Deliv Rev. 2011 Apr 30;63(4-5):324-30. doi: 10.1016/j.addr.2011.01.013. Epub 2011 Mar 1. Review.

6.

Progress in the reprogramming of somatic cells.

Ma T, Xie M, Laurent T, Ding S.

Circ Res. 2013 Feb 1;112(3):562-74. doi: 10.1161/CIRCRESAHA.111.249235. Review.

7.

Disease-specific induced pluripotent stem cells: a platform for human disease modeling and drug discovery.

Jang J, Yoo JE, Lee JA, Lee DR, Kim JY, Huh YJ, Kim DS, Park CY, Hwang DY, Kim HS, Kang HC, Kim DW.

Exp Mol Med. 2012 Mar 31;44(3):202-13. doi: 10.3858/emm.2012.44.3.015.

8.

Inducing pluripotency for disease modeling, drug development and craniofacial applications.

Rosa V, Toh WS, Cao T, Shim W.

Expert Opin Biol Ther. 2014 Sep;14(9):1233-40. doi: 10.1517/14712598.2014.915306. Epub 2014 May 22. Review.

PMID:
24850281
9.

Human pluripotent stem cells as tools for neurodegenerative and neurodevelopmental disease modeling and drug discovery.

Corti S, Faravelli I, Cardano M, Conti L.

Expert Opin Drug Discov. 2015 Jun;10(6):615-29. doi: 10.1517/17460441.2015.1037737. Epub 2015 Apr 20. Review.

PMID:
25891144
10.

Concise review: drug discovery in the age of the induced pluripotent stem cell.

Ko HC, Gelb BD.

Stem Cells Transl Med. 2014 Apr;3(4):500-9. doi: 10.5966/sctm.2013-0162. Epub 2014 Feb 3. Review.

11.

Recent technological updates and clinical applications of induced pluripotent stem cells.

Diecke S, Jung SM, Lee J, Ju JH.

Korean J Intern Med. 2014 Sep;29(5):547-57. doi: 10.3904/kjim.2014.29.5.547. Epub 2014 Aug 28. Review.

12.

Induced pluripotent stem cells as a disease modeling and drug screening platform.

Ebert AD, Liang P, Wu JC.

J Cardiovasc Pharmacol. 2012 Oct;60(4):408-16. doi: 10.1097/FJC.0b013e318247f642. Review.

13.

Induced pluripotent stem cells: applications in regenerative medicine, disease modeling, and drug discovery.

Singh VK, Kalsan M, Kumar N, Saini A, Chandra R.

Front Cell Dev Biol. 2015 Feb 2;3:2. doi: 10.3389/fcell.2015.00002. eCollection 2015. Review.

14.

Evolution of induced pluripotent stem cell technology.

Zhou H, Ding S.

Curr Opin Hematol. 2010 Jul;17(4):276-80. doi: 10.1097/MOH.0b013e328339f2ee. Review.

PMID:
20442654
15.

Combining small molecules for cell reprogramming through an interatomic analysis.

Feltes BC, Bonatto D.

Mol Biosyst. 2013 Nov;9(11):2741-63. doi: 10.1039/c3mb70159j.

PMID:
24056910
16.

Induced pluripotent stem cells (iPSCs): the emergence of a new champion in stem cell technology-driven biomedical applications.

Das AK, Pal R.

J Tissue Eng Regen Med. 2010 Aug;4(6):413-21. doi: 10.1002/term.258. Review.

PMID:
20084623
17.

Reprogram or reboot: small molecule approaches for the production of induced pluripotent stem cells and direct cell reprogramming.

Jung DW, Kim WH, Williams DR.

ACS Chem Biol. 2014 Jan 17;9(1):80-95. doi: 10.1021/cb400754f. Epub 2013 Nov 22. Review.

PMID:
24245936
18.

iPSC technology: platform for drug discovery. Point.

Ellis J, Bhatia M.

Clin Pharmacol Ther. 2011 May;89(5):639-41. doi: 10.1038/clpt.2011.22.

PMID:
21512521
19.

The use of induced pluripotent stem cells in drug development.

Inoue H, Yamanaka S.

Clin Pharmacol Ther. 2011 May;89(5):655-61. doi: 10.1038/clpt.2011.38. Epub 2011 Mar 23. Review.

PMID:
21430656
20.

Induced pluripotent stem cell technology for disease modeling and drug screening with emphasis on lysosomal storage diseases.

Huang HP, Chuang CY, Kuo HC.

Stem Cell Res Ther. 2012 Aug 28;3(4):34. doi: 10.1186/scrt125. Review.

Items per page

Supplemental Content

Write to the Help Desk